Rentosertib
Idiopathic Pulmonary Fibrosis · TNIK Inhibition (AI-discovered)
Clinical trials
1
Mechanism
TNIK Inhibition (AI-discovered)
Development stage
Phase IIa (Nature Medicine 2025)
Evidence level
Level 2 (Phase IIa)
Developer
Insilico Medicine
Overview
FIRST AI-DISCOVERED DRUG validated in clinical trial. Published Nature Medicine June 2025. 60mg QD: mean FVC change +98.4 mL vs -20.3 mL placebo. Novel target TNIK discovered entirely by generative AI (Pharma.AI). Historic milestone for AI drug discovery.
Rentosertib clinical trials
Explore related
Medical disclaimer. This page summarizes research about Rentosertib for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.